Bladder cancer incidence statistics

Cases

New cases of bladder cancer, 2014, UK

 

Proportion of all cases

Percentage bladder cancer is of total cancer cases, 2014, UK

 

Age

Peak rate of bladder cancer cases, 2012-2014, UK

 

Trend over time

Change in bladder cancer incidence rates since the early 1990s, UK

Bladder cancer is the tenth most common cancer in the UK (2014), accounting for 3% of all new cases. In males, it is the eighth most common cancer (4% of all male cases), whilst it is the 15th most common cancer in females (2% of female cases).[1-4]

In 2014, there were 10,063 new cases of bladder cancer in the UK: 7,307 (73%) in males and 2,756 (27%) in females, giving a male:female ratio of around 27:10.[1-4] The crude incidence rate Open a glossary item shows that there are 23 new bladder cancer cases for every 100,000 males in the UK, and 8 for every 100,000 females.

The European age-standardised incidence rate Open a glossary item (AS rate) in males, is significantly higher in England compared with Scotland and Northern Ireland.[1-4] Rates for females are are significantly higher in Scotland compared with England and Northern Ireland.

Bladder Cancer (C67), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2014

England Wales Scotland Northern Ireland UK
Male Cases 6,242 367 556 142 7,307
Crude Rate 23.3 24.1 21.4 15.7 23.0
AS Rate 29.1 26.5 26.0 21.6 28.5
AS Rate - 95% LCL 28.4 23.8 23.8 18.1 27.9
AS Rate - 95% UCL 29.8 29.2 28.2 25.2 29.2
Female Cases 2,272 140 288 56 2,756
Crude Rate 8.2 8.9 10.5 6.0 8.4
AS Rate 8.2 8.0 10.2 6.6 8.4
AS Rate - 95% LCL 7.9 6.7 9.1 4.8 8.0
AS Rate - 95% UCL 8.6 9.4 11.4 8.3 8.7
Persons Cases 8,514 507 844 198 10,063
Crude Rate 15.7 16.4 15.8 10.8 15.6
AS Rate 17.4 16.2 16.9 13.4 17.2
AS Rate - 95% LCL 17.0 14.8 15.8 11.5 16.8
AS Rate - 95% UCL 17.7 17.6 18.1 15.2 17.5

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

For bladder cancer, like most cancer types, differences between countries largely reflect risk factor prevalence in years past.

References

  1. Data were provided by the Office for National Statistics on request, June 2016. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, May 2016. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, June 2016. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2016. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/

About this data

Data is for: UK, 2014, ICD-10 C67

Last reviewed:

Bladder cancer incidence is strongly related to age, with the highest incidence rates being in older males and females. In the UK in 2012-2014, on average each year more than half (54%) of cases were diagnosed in people aged 75 and over.[1-4]

Age-specific incidence rates rise gradually from around age 50-54 in both males and females, with a sharper rise in males from age 60-64, peaking in males and females in the 90+ age group. Incidence rates are higher for males than for females in those aged 40-44 and over (the difference is not significant in younger age groups) and this gap is widest at age 80-84, when the male:female incidence ratio of age-specific rates (to account for the different proportions of males to females in each age group) is around 37:10.[1-4]

Bladder Cancer (C67), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2012-2014

For bladder cancer, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

References

  1. Data were provided by the Office for National Statistics on request, June 2016. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases.
  2. Data were provided by ISD Scotland on request, May 2016. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, June 2016. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2016. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2012-2014, ICD-10 C67

Last reviewed:

Bladder cancer incidence rates have decreased by 38% in the UK since the early 1990s.[1-3] This includes a larger overall increase for males than females. Bladder cancer incidence rates increased by 19% (persons) in Great Britain between 1979-1981 and 1991-1993.[1-3]

For males, European age-standardised (AS) Open a glossary item incidence rates rates decreased by 42% between 1993-1995 and 2012-2014. The decrease is smaller for females, with rates decreasing by 36% during this time.

Over the last decade in the UK (between 2003-2005 and 2012-2014), bladder cancer AS incidence rates have decreased by 12% for both sexes combined, and by 15% and 13% in males and females respectively.[1-4]

Bladder Cancer (C67), European Age-Standardised Incidence Rates, UK, 1993-2014​

Bladder cancer incidence rates have decreased overall for all of the broad age groups in males in the UK since the early 1990s.[1-4] The largest decrease has been in men aged 50-59, with European AS incidence rates falling by 61% between 1993-1995 and 2012-2014.

Bladder Cancer (C67), European Age-Standardised Incidence Rates, Males, by Age, UK, 1993-2014

Bladder cancer incidence rates have also decreased overall for all of the broad age groups in females in the UK since the early 1990s.[1-4] The largest increase has been in females aged 60-69, with European AS incidence rates falling by 52% between 1993-1995 and 2012-2014.

Bladder Cancer (C67), European Age-Standardised Incidence Rates, Females, by Age, UK, 1993-2014

For bladder cancer, like most cancer types, incidence trends largely reflect changing prevalence of risk factors and improvements in diagnosis and data recording. Recent incidence trends are influenced by risk factor prevalence in years past, and trends by age group reflect risk factor exposure in birth cohorts.

References

  1. Data were provided by the Office for National Statistics on request, June 2016. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, May 2016. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, June 2016. Similar data can be found here: http://www.wcisu.wales.nhs.uk
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2016. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/

About this data

Data is for UK, 1993-2014, ICD-10 C67

Last reviewed:

Overall stage at diagnosis

A high proportion (82%) of bladder cancer cases in England and Northern Ireland have stage at diagnosis recorded.[1,2]

Bladder cancer patients with a known stage at diagnosis are most commonly diagnosed at stage I (47-48%). More bladder cancer patients with a known stage are diagnosed at an early stage (73-76% are diagnosed at stage I or II), than a late stage (24-28% are diagnosed at stage III or IV). Between 17% and 20% of bladder cancer patients have metastases at diagnosis (stage IV).[1,2]

The stage distribution for each cancer type will reflect many factors including how the cancer type develops, the way symptoms appear, public awareness of symptoms, how quickly a person goes to see their doctor and how quickly the cancer is recognised and diagnosed by a doctor. It might also relate to whether a national screening programme that can detect early stage disease exists for that cancer type, along with the extent of uptake of that programme.

A cancer type associated with a large proportion of early stage diagnoses could be one that is more likely to be symptomatic at an earlier stage of development, with recognisable symptoms rather than more generic ones.

Bladder Cancer (C67), Proportion of Cases Diagnosed at Each Stage, All Ages, England 2014 and Northern Ireland 2012-2014

Data should not be compared between countries due to differences in time periods and possible differences in recording of stage at diagnosis.

References

  1. National Cancer Registration and Analysis Service. Stage Breakdown by CCG 2014. London: NCIN; 2016
  2. Northern Ireland Cancer Registry, Queens University Belfast, Incidence by stage 2010-2014. Belfast: NICR; 2016 

About this data

Data is for: England 2014, Northern Ireland 2010-2014, ICD-10 C67

Data is not comparable between countries due to differences in time periods and possible differences in how countries record stage at diagnosis.

Last reviewed:

Bladder cancer incidence rates are projected to fall by 34% in the UK between 2014 and 2035, to 13 cases per 100,000 people by 2035.[1] This includes a larger decrease for males than for females.

For males, bladder cancer European age-standardised (AS) Open a glossary item incidence rates in the UK are projected to fall by 38% between 2014 and 2035, to 21 cases per 100,000 by 2035.[1] For females, rates are projected to fall by 31% between 2014 and 2035, to 7 cases per 100,000 by 2035.[1]

Bladder cancer (C67), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

 

It is projected that 10,386 cases of bladder cancer (7,531 in males, 2,855 in females) will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C67

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as "increase" or "decrease" if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

The lifetime risk of developing bladder cancer is 1 in 39 for men and around 1 in 110 for women, in 2012 in the UK.[1]

The lifetime risk for bladder cancer has been calculated to account for the possibility that someone can have more than one diagnosis of bladder cancer over the course of their lifetime (‘Adjusted for Multiple Primaries’ (AMP) method).[2]

References

  1. Lifetime risk estimates calculated by the Statistical Information Team at Cancer Research UK. Based on data provided by the Office of National Statistics, ISD Scotland, the Welsh Cancer Intelligence and Surveillance Unit and the Northern Ireland Cancer Registry, on request, December 2013 to July 2014.
  2. Sasieni PD, Shelton J, Ormiston-Smith N, et al. What is the lifetime risk of developing cancer?: The effect of adjusting for multiple primaries. Br J Cancer, 2011. 105(3): p. 460-5.
Last reviewed:

There is evidence for an association between bladder cancer incidence and deprivation for both males and females in England.[1] England-wide data for 2006-2010 show European age-standardised Open a glossary item  incidence rates are 27% higher for males living in the most deprived areas compared with the least deprived, and 43% higher for females.[1]

Bladder Cancer (C67), European Age-Standardised Incidence Rates by Deprivation Quintile, England, 2006-2010

The estimated deprivation gradient in bladder cancer incidence between people living in the most and least deprived areas in England has not changed in the period 1996-2010.[1] It has been estimated that there would have been around 730 fewer cancer cases each year in England during 2006-2010 if all people experienced the same incidence rates as the least deprived.[1

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for UK, 2006-2010, ICD-10 C67

Deprivation gradient statistics were calculated using incidence data for 2006-2010. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report

Last reviewed:

Age-standardised rates for White males with bladder cancer range from 19.9 to 20.5 per 100,000. Rates for Asian males are significantly lower, ranging from 6.5 to 10.1 per 100,000 and the rates for Black males are also significantly lower, ranging from 5.6 to 9.6 per 100,000. For females there is a similar pattern - the age-standardised rates for White females range from 5.7 to 6.0 per 100,000, and rates for Asian and Black females are also significantly lower ranging from 1.3 to 2.7 per 100,000 and 1.6 to 3.7 per 100,000 respectively.[1]

Ranges are given because of the analysis methodology used to account for missing and unknown data. For bladder cancer, 42,339 cases were identified; 14% had no known ethnicity.

Last reviewed:

In the UK more than 46,500 people were still alive at the end of 2006, up to ten years after being diagnosed with bladder cancer.[1]

Bladder Cancer (C67), One, Five and Ten Year Cancer Prevalence, UK, 31st December 2006

1 Year Prevalence 5 Year Prevalence 10 Year Prevalence
Male 5,514 20,040 34,932
Female 1,913 6,453 11,608
Persons 7,427 26,493 46,540

Worldwide, it is estimated that there were nearly 1.2 million cancer patients still alive in 2008, up to five years after their diagnosis.[2]

References

  1. National Cancer Intelligence Network (NCIN). One, Five and Ten Year Cancer Prevalence by Cancer Network, UK, 2006. London: NCIN; 2010.
  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.10 [Internet]. Lyon, France: International Agency for Research on Cancer (IARC): 2010. Available from http://globocan.iarc.fr. Accessed May 2011.
Last reviewed:

Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). In Europe (2012), the highest World age-standardised incidence rates for bladder cancer are in Belgium for men and Hungary for women; the lowest rates are in the United Kingdom for men and the Ukraine for women. UK bladder cancer incidence rates are estimated to be the lowest in males in Europe, and 13th lowest in females.[1] These data are broadly in line with Europe-specific data available elsewhere.[2]

Bladder cancer is the 9th most common cancer worldwide, with around 429,800 new cases diagnosed in 2012 (3% of the total). Bladder cancer incidence rates are highest in Southern Europe and lowest in Western Africa, but this partly reflects varying data quality worldwide.[1]

Variation between countries may reflect difference prevalence of risk factors, use of screening, and diagnostic methods.

References

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed December 2013.
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al.Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer (2013) 49, 1374-1403.
Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

Rate this page:

Currently rated: 2.4 out of 5 based on 12 votes
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page